comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 01:07:24 - browse：73378

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： State of the Union pitch: Bigger Medicare drug price negotiations

focus

WSS

Fentanyl is making it harder to start addiction treatment

Scrutiny of post

Addressing health care workers' trauma can help fight burnout

Digital health: a case of mistaken identity

Addressing health care workers' trauma can help fight burnout

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

explore

comprehensive

hotspot

Supreme Court strikes down use of affirmative action

For longer

New air purifier tech could be key to improving indoor air quality

$1 billion proposal to grow Boston, Massachusetts biotech

Medicare proposal to cover medical devices draws a mixed reaction

Families look for replacement for GSK asthma drug Flovent

The cancer drug shortage isn’t new — and neither are the solutions

Fetal cell organoids grown from amniotic fluid, study finds

State Dept. review finds Biden bears some blame for Afghanistan failures

A new approach to psychiatric drug development

focus

Longer MASH drug regimen improved liver, Akero study finds

At flashy new research hub, AstraZeneca lays out ambitious growth goals

A new approach to psychiatric drug development

H5N1 bird flu outbreak: Second human case reported, in Michigan

Change Healthcare: What is it, why does its cyberattack matter?

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

focus

focus

knowledge

focus